Total laparoscopic radical resection of hilar cholangiocarcinoma: preliminary experience of a single center.


Journal

BMC surgery
ISSN: 1471-2482
Titre abrégé: BMC Surg
Pays: England
ID NLM: 100968567

Informations de publication

Date de publication:
24 Aug 2024
Historique:
received: 29 05 2024
accepted: 14 08 2024
medline: 26 8 2024
pubmed: 26 8 2024
entrez: 24 8 2024
Statut: epublish

Résumé

The aim of this study was to describe our preliminary experience in the procedure of laparoscopic radical resection of hilar cholangiocarcinoma and to evaluate its feasibility, safety, and clinical efficacy. A retrospective analysis was conducted on 44 patients with hilar cholangiocarcinoma who underwent laparoscopic surgery at our hospital from August 2019 to September 2023. Clinical data were collected from these patients, including 13 cases of Bismuth type I, 17 cases of Bismuth type II, 5 cases of Bismuth type IIIa, and 9 cases of Bismuth type IIIb. Laparoscopic radical resection of hilar cholangiocarcinoma was successfully performed in 38 patients (86.3%). Among the remaining patients, 3 required vascular reconstruction to complete radical surgery and were converted to laparotomies, while 3 others underwent T-tube drainage only due to unresectable metastases. The median operation time was 285 min (range, 190-450), and the median estimated blood loss was 360 mL (range, 260-1200). The postoperative hospital stay duration was 14.3 ± 3.6 days. No perioperative mortality was observed. Postoperative pathological examination revealed negative microscopic margins (R0) in 39 cases and positive microscopic margins (R1) in 2 cases. Postoperative complications occurred in 8 patients (18.1%), with 4 cases (9.0%) of Grade I, 3 cases (6.8%) of Grade II, 1 case (2.2%) of Grade IIIa, and no Grade IIIb or IV complications. The median overall survival for patients who underwent radical R0 resection was 30.4 months (range, 5.3-43.6). The Disease-free survival rates were 73.6% at 1 year, 61.2% at 2 years, and 40.1% at 3 years. Total laparoscopic radical resection of hilar cholangiocarcinoma can be performed safely, feasibly, and effectively by experienced surgeons after an accurate preoperative evaluation.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to describe our preliminary experience in the procedure of laparoscopic radical resection of hilar cholangiocarcinoma and to evaluate its feasibility, safety, and clinical efficacy.
METHODS METHODS
A retrospective analysis was conducted on 44 patients with hilar cholangiocarcinoma who underwent laparoscopic surgery at our hospital from August 2019 to September 2023. Clinical data were collected from these patients, including 13 cases of Bismuth type I, 17 cases of Bismuth type II, 5 cases of Bismuth type IIIa, and 9 cases of Bismuth type IIIb.
RESULTS RESULTS
Laparoscopic radical resection of hilar cholangiocarcinoma was successfully performed in 38 patients (86.3%). Among the remaining patients, 3 required vascular reconstruction to complete radical surgery and were converted to laparotomies, while 3 others underwent T-tube drainage only due to unresectable metastases. The median operation time was 285 min (range, 190-450), and the median estimated blood loss was 360 mL (range, 260-1200). The postoperative hospital stay duration was 14.3 ± 3.6 days. No perioperative mortality was observed. Postoperative pathological examination revealed negative microscopic margins (R0) in 39 cases and positive microscopic margins (R1) in 2 cases. Postoperative complications occurred in 8 patients (18.1%), with 4 cases (9.0%) of Grade I, 3 cases (6.8%) of Grade II, 1 case (2.2%) of Grade IIIa, and no Grade IIIb or IV complications. The median overall survival for patients who underwent radical R0 resection was 30.4 months (range, 5.3-43.6). The Disease-free survival rates were 73.6% at 1 year, 61.2% at 2 years, and 40.1% at 3 years.
CONCLUSION CONCLUSIONS
Total laparoscopic radical resection of hilar cholangiocarcinoma can be performed safely, feasibly, and effectively by experienced surgeons after an accurate preoperative evaluation.

Identifiants

pubmed: 39182023
doi: 10.1186/s12893-024-02533-w
pii: 10.1186/s12893-024-02533-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241

Informations de copyright

© 2024. The Author(s).

Références

Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M. Vauthey JN. hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17(8):691–9.
Kovalenko YA, Zharikov YO, Konchina NA, Gurmikov BN, Marinova LA, Zhao AV. Perihilar cholangiocarcinoma: a different concept for radical resection. Surg Oncol. 2020;33:270–5.
doi: 10.1016/j.suronc.2020.02.013 pubmed: 32561092
Groot Koerkamp B, Wiggers JK, Gonen M, Doussot A, Allen PJ, Besselink MG, Blumgart LH, Busch OR, D’Angelica MI, DeMatteo RP, Gouma DJ, Kingham TP, van Gulik TM, Jarnagin WR. Survival after resection of perihilar cholangiocarcinoma-development and external validation of a prognostic nomogram. Ann Oncol. 2016;27(4):753.
doi: 10.1093/annonc/mdw063 pubmed: 26920702 pmcid: 4803457
Buettner S, van Vugt JLA, Gaspersz MP, Coelen RJS, Roos E, Labeur TA, Margonis GA, Ethun CG, Maithel SK, Poultsides G, Tran T, Idrees K, Isom CA, Fields RC, Krasnick BA, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, IJzermans JNM, van Gulik TM, Pawlik TM, Groot Koerkamp B. Survival after resection of perihilar cholangiocarcinoma in patients with lymph node metastases. HPB (Oxford). 2017;19(8):735–40.
doi: 10.1016/j.hpb.2017.04.014 pubmed: 28549744 pmcid: 5907486
Melloul E, Lassen K, Roulin D, Grass F, Perinel J, Adham M, Wellge EB, Kunzler F, Besselink MG, Asbun H, Scott MJ, Dejong CHC, Vrochides D, Aloia T, Izbicki JR, Demartines N. Guidelines for Perioperative Care for Pancreatoduodenectomy: enhanced recovery after surgery (ERAS) recommendations 2019. World J Surg. 2019;44(7):2056–84.
doi: 10.1007/s00268-020-05462-w
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13.
doi: 10.1097/01.sla.0000133083.54934.ae pubmed: 15273542 pmcid: 1360123
Reich H, McGlynn F, J DeCaprio,R Budin. Laparoscopic excision of benign liver lesions. Obstet Gynecol. 1991;78:956–8.
pubmed: 1833688
Zhang Y, Dou C, Wu W, Liu J, Jin L, Hu Z, Zhang C. Total laparoscopic versus open radical resection for hilar cholangiocarcinoma. Surg Endosc. 2020;34(10):4382–7.
doi: 10.1007/s00464-019-07211-0 pubmed: 31664578
Chen Y, Xu Y, Zhang Y. Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China. Biosci Trends. 2020;14(3):168–73.
doi: 10.5582/bst.2020.03010 pubmed: 32389939
Sucher R, Scheuermann U, Seehofer D. Total laparoscopic resection of Hilar Cholangiocarcinoma Type 3b: applying a parachute technique for Hepaticojejunostomy. Ann Surg Oncol. 2021;28(4):2030–4.
doi: 10.1245/s10434-020-09175-1 pubmed: 33000370
Machado MA, Makdissi FF, Surjan RC. Totally laparoscopic right hepatectomy with Roux-en-Y hepaticojejunostomy for fight-sided intraductal papillary mucinous neoplasm of the bile duct. Ann Surg Oncol. 2014;21(6):1841–3.
doi: 10.1245/s10434-014-3517-9 pubmed: 24522989
Du Y, Wang J, Li Y, Ma HQ, Liu L, Zhu YX, Zhao WX. Clinical application of a modified pancreatojejunostomy technique for laparoscopic pancreaticoduodenectomy. HPB (Oxford). 2019;21(10):1336–43.
doi: 10.1016/j.hpb.2019.02.006 pubmed: 30833188
Wang J, Ma HQ, Liu L, Zhu YX, Zhao WX. Total laparoscopic pancreaticoduodenectomy: a report of 111 cases in a single center. Chin J Gen Surg. 2019;34(12):1035–9.
Park MJ, Kim YK, Lim S, Rhim H, Lee WJ. Hilar cholangiocarcinoma: value of adding DW imaging to gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. Radiology. 2014;270(3):768–76.
Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250(2):210–8.
Ramos Rubio E. Radical surgery for hilar cholangiocarcinoma (klatskin tumor). Cir Esp. 2007;82(1):11–5.
doi: 10.1016/S0009-739X(07)71654-8 pubmed: 17580025
Noji T, Tsuchikawa T, Okamura K, Shichinohe T, Tanaka E, Hirano S. Surgical outcome of hilar plate resection: extended hilar bile duct resection without hepatectomy. J Gastrointest Surg. 2014;18(6):1131–7.
doi: 10.1007/s11605-014-2490-8 pubmed: 24627257
Fong ZV, Brownlee SA, Qadan M, Tanabe KK. The Clinical Management of Cholangiocarcinoma in the United States and Europe: a Comprehensive and evidence-based comparison of guidelines. Ann Surg Oncol. 2021;28(5):2660–74.
doi: 10.1245/s10434-021-09671-y pubmed: 33646431
Ramanathan R, Borrebach J, Tohme S, Tsung A. Preoperative biliary drainage is Associated with increased complications after Liver Resection for Proximal Cholangiocarcinoma. J Gastrointest Surg. 2018;22(11):1950–7.
doi: 10.1007/s11605-018-3861-3 pubmed: 29980975 pmcid: 6224307
Gaspersz MP, Buettner S, van Vugt JLA, de Jonge J, Polak WG, Doukas M, Ijzermans JNM, Koerkamp BG, Willemssen FEJA. Evaluation of the New American Joint Committee on Cancer Staging Manual 8th Edition for Perihilar Cholangiocarcinoma. J Gastrointest Surg. 2020;24(7):1612–8.
doi: 10.1007/s11605-019-04127-x pubmed: 30756314
Yoshida T, Matsumoto T, Sasaki A, Morii Y, Shibata K, Ishio T, Kitano S. Lymphatic spread differs according to tumor location in extrahepatic bile duct cancer. Hepatogastroenterology. 2003;50(49):17–20.
pubmed: 12629981
Kadaba RS, Bowers KA, Khorsandi S, Hutchins RR, Abraham AT, Sarker SJ, Bhattacharya S, Kocher HM. Complications of biliary-enteric anastomoses. Ann R Coll Surg Engl. 2017;99(3):210–5.
doi: 10.1308/rcsann.2016.0293 pubmed: 27659373
Feng F, Cao X, Liu X, Qin J, Zhang S, Li Q, Liu J. Laparoscopic resection for Bismuth type III and IV hilar cholangiocarcinoma: how to improve the radicality without direct palpation. J Surg Onco. 2019;120(8):1379–85.
doi: 10.1002/jso.25739
Zhang J, Guo X, Wang H, Zhang J, Liu P, Qiao Q, Wang X. The application of three-Dimensional visualization in preoperative evaluation of Portal Vein Invasion in Hilar Cholangiocarcinoma. Cancer Manag Res. 2020;12:9297–302.
doi: 10.2147/CMAR.S264479 pubmed: 33061619 pmcid: 7533901

Auteurs

Yusheng Du (Y)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China.

Ji Wang (J)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China.

Li Liu (L)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China.

Hongqin Ma (H)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China.

Wenxing Zhao (W)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China. wxzhaosurgy@163.com.

Ying Li (Y)

Department of General Surgery, Affiliated Hospital of Xuzhou Medical University, #99 Huai Xi Road, Jiangsu, Xuzhou, 221002, P. R. China. 343335502@qq.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH